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Abstract
Background: Iron is essential for life but contributes to oxidative damage. In Northern-European ancestry populations, HFE gene C282Y 
mutations are relatively common (0.3%–0.6% rare homozygote prevalence) and associated with excessive iron absorption, fatigue, diabetes, 
arthritis, and liver disease, especially in men. Iron excess can be prevented or treated but diagnosis is often delayed or missed. Data on 
sarcopenia, pain, and frailty are scarce.
Methods: Using 200,975 UK Biobank volunteers aged 60–70 years, we tested associations between C282Y homozygosity with Fried frailty, 
sarcopenia, and chronic pain using logistic regression adjusted for age and technical genetic covariates. As iron overload is progressive (with 
menstruation protective), we included specific analyses of older (65–70 years) females and males.
Results: One thousand three hundred and twelve (0.65%) participants were C282Y homozygotes; 593 were men (0.62%) and 719 were 
women (0.68%). C282Y homozygote men had increased likelihoods of reporting chronic pain (odds ratio [OR] 1.23: 95% confidence interval 
[CI] 1.05–1.45, p = .01) and diagnoses of polymyalgia rheumatica, compared to common “wild-type” genotype. They were also more likely 
to have sarcopenia (OR 2.38: 1.80–3.13, p = 9.70 × 10−10) and frailty (OR 2.01: 1.45–2.80, p = 3.41 × 10−05). C282Y homozygote women 
(n = 312, 0.7%) aged 65–70 were more likely to be frail (OR 1.73: 1.05–2.84, p = .032) and have chronic knee, hip, and back pain. Overall, 
1.50% of frail men and 1.51% of frail women in the 65–70 age group were C282Y homozygous.
Conclusions: HFE C282Y homozygosity is associated with substantial excess sarcopenia, frailty, and chronic pain at older ages. Given the 
availability of treatment, hereditary hemochromatosis is a strong candidate for precision medicine approaches to improve outcomes in late life.
Keywords: Muscle, Epidemiology, Genetics, Physical function, UK Biobank
Hereditary hemochromatosis (HH) is characterized by iron accu-
mulation and deposition in parenchymal tissues (1). In European 
ancestry populations, HH is predominantly caused by an autoso-
mal recessive mutation in the HFE gene (C282Y) (2,3), present in 
5%–15% of the population, with 0.3%–0.6% homozygote and at 
highest risk of HH (4). The prevalence of this variant is highest in 
Northern Europe, especially in Britain and Ireland. The prevalence 
of C282Y homozygosity is 0.26% in the U.S. population (5), and 
HH is one of the most common genetic diseases in North America.
Symptoms of C282Y-associated HH usually appear in men aged 
over 40 years and in postmenopausal women. The typical presenta-
tion of clinical HH includes liver cirrhosis, diabetes mellitus, and 
skin pigmentation (6), although many cases are now identified on 
biochemical measures (high ferritin and transferrin saturation) in 
D
ow
nloaded from
 https://academ
ic.oup.com
/biom
edgerontology/article-abstract/74/3/337/5288441 by guest on 18 February 2019
patients presenting with fatigue (6). Some studies have suggested 
that many individuals with the C282Y genotype do not develop 
clinical disease (7,8), but a recent review suggested that the life-
time risk of serious liver disease in men is approximately 9% (9). 
In a study of genotyped patients in the eMERGE network, includ-
ing clinical biobanks across seven U.S. cohorts (10) (n = 106 being 
C282Y homozygote) survival curve analyses to age 90 suggested that 
50% of the males and approximately 25% of the female p.C282Y 
homozygotes were eventually diagnosed with hemochromatosis 
(mean age at diagnosis 61.5  years old). The lower penetrance in 
women is attributed to the iron loss occurring in menstruation and 
having children (6,11). Phlebotomy provides effective prevention 
and treatment for many features of HH if started before tissue dam-
age occurs (12), but population screening for HH is not encouraged, 
and many sufferers are diagnosed late in the course of the disease, or 
misdiagnosed (6,13).
Although iron is essential for life, excess intracellular iron is a 
powerful contributor to oxidative damage, a hallmark process of 
aging (14). Iron has also been linked to the inflammatory response 
and to mitochondrial dysfunction, and it accumulates during cellular 
senescence (15). As a result, iron accumulation upregulates at least 
three different biological hallmarks of aging (16). Nevertheless, to 
the best of our knowledge, no population studies of the C282Y HFE 
mutation for associations with common geriatric syndromes have 
yet been done.
In the current study, we aimed to estimate C282Y associations 
with sarcopenia, frailty, and chronic pain, in older people, aged 
60–70 years, from UK Biobank.
Methods
Introducing Cohort
Data used in this cross-sectional study are from the UK Biobank—a 
large community-based volunteer cohort of 502,642 people aged 
40–70 years, recruited through 22 assessment centers across England, 
Wales, and Scotland. For this analysis, we included all subjects of 
European descent aged 60 to 70 years at baseline with genotyping 
data (n = 200,975) (17). At baseline, demographics, lifestyle, disease 
history, and physiological measurements were recorded. Informed 
consent was given for genotyping, and data linkage to medical records. 
Prevalent HH diagnoses were ascertained by participants self-reports 
on the baseline questionnaire, plus ICD-10 coded inpatient hospital 
records from 1996 to baseline interview. There is a selection bias in 
this data set as UK Biobank volunteers tended to be healthier at base-
line than the general UK population (18). Participants were notified 
of health-related findings at baseline, but not the results of genotyp-
ing. Ethical approval for UK Biobank was obtained from the North 
West Multi-Centre Research Ethics Committee.
Genotyping
Genotyping and imputation were performed by the UK Biobank 
team (19). Briefly, two custom Affymetrix microarrays (>95 identi-
cal) directly genotyped over 800,000 genetic variants in 488,377 of 
the UK Biobank participants. Genotype imputation was successfully 
performed in 487,442 participants, using the Haplotype Reference 
Consortium panel to infer nearly 40 million genotypes for genetic 
variants not directly measured, including the HFE variant C282Y 
(rs1800562). We previously identified 451,243 of these participants 
as being of European descent (20) who were taken forward for 
analysis.
Outcome Ascertainment
We tested four main outcomes: chronic pain, polymyalgia rheu-
matica, Fried definition frailty, and sarcopenia, as these are some 
of the main geriatric syndromes affecting the elderly population. 
Additional outcomes we tested in exploratory analysis included five 
individual frailty components and five specific sites of chronic pain.
Chronic pain was defined as participants reporting site-specific 
pain that lasted for more than 3 months (yes/no response) in one 
or more sites (hip, knee, headache, back, and neck/shoulder pain). 
Prevalent polymyalgia rheumatica was based on self-reported diag-
noses on the baseline questionnaire and ICD-10 coded inpatient hos-
pital records from 1996 to baseline interview.
We modified the Fried Frailty phenotype definition (21) according 
to the data available in UK Biobank. Our definition of Fried Frailty 
was presence of three or more of: self-reported weight loss, self-
reported exhaustion, self-reported slow walking pace, self-reported 
low physical activity (lowest 20%, sex-specific), and low measured 
grip strength (lowest 20%, sex-specific). For weight loss, the ques-
tion was “Compared with one year ago, has your weight changed?” 
Response “No” and “Yes – gained weight” coded as no weight loss. 
Response “Yes – weight loss” coded as yes. For the exhaustion meas-
ure, the question was “Over the past two weeks, how often have you 
felt tired or had little energy?” and responses “more than half the 
days,” “nearly every day” were coded as “Yes.” For the slow walk-
ing pace measure participants were asked “How would you describe 
your usual walking pace?” with the options “slow pace,” “steady 
average pace,” “brisk pace.” Response “slow pace” was used in the 
frailty phenotype. For these self-reported measures, responses “do 
not know” and “prefer not to answer” were excluded. Participants 
reported frequency and duration of walking, moderate activity, 
and vigorous activity based on the validated International Physical 
Activity Questionnaire (22). Total metabolic equivalent (MET) min-
utes of exercise per week were calculated and categorized into sex-
specific quintiles of physical activity. Grip strength was measured in 
both hands using a hydraulic hand dynamometer and the maximum 
reading was used. For the Fried frailty phenotype, participants were 
only included in analyses if they had data on all five individual com-
ponents (n = 172,384/200,975) (see Supplementary Table 1).
Sarcopenia was defined using the European Working Group 
on Sarcopenia in Older People (EWGSOP) definition, encompass-
ing measures of low muscle mass (measured by bioimpedance using 
a Tanita BC 418ma body composition analyser) and low muscle 
strength (measured by grip strength as described above) (23). Low 
skeletal muscle mass index, as defined by Janssen (24), was defined 
as <8.87  kg/m2 in males and <6.42  kg/m2 in females. Low grip 
strength was defined as <30 kg in males and <20 kg in females (23).
Statistical Analysis
We tested baseline associations between C282Y homozygosity and 
outcomes using logistic regression models. These were adjusted for 
covariates including population substructure using the first five 
principal components generated in Northern European descent 
participants, genotyping microarray (Affymetrix Axiom array 90% 
participants, Affymetrix BiLEVE array, sharing >95% content). In 
our overall analysis, we compared C282Y homozygotes against wild 
type (homozygous common) as the reference group. We analyzed 
men and women separately. As iron overload is cumulative over 
time (and therefore with advancing age), but menstruation reduces 
iron stores, we have included specific analyses of older (65–70 years) 
female and male groups, the 60–64 year olds, and the whole group 
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together (60–70). We tested C282Y homozygosity status for inter-
actions with daily alcohol intake and smoking status for the four 
main outcomes, since these environmental exposures may exacer-
bate C282Y iron overload and clinical outcomes (6,25). We consid-
ered a p value less than .05 as statistically significant. Analyses used 
Stata v14.1 (26). Figures were generated in R v3.4.1 using package 
“metaphor” (v2.0) (27).
Results
There were 200,975 UK Biobank participants aged 60–70 at base-
line with genotype data who could be included in the analyses: of 
these 1,312 (0.65% or 1 in 153)  were C282Y homozygotes; 593 
were men and 719 were women (Table 1). Self-reported or hospital-
recorded diagnoses of hemochromatosis at baseline were present for 
193 participants (0.1% of 200,975). 99.9% of homozygote women 
between the ages of 60–70 years were postmenopausal (including 
posthysterectomy), and the mean age at menopause was 49.9 years 
(SD 5.39). The number of participants with missing data on any of 
the outcomes, by sex, can be found in Supplementary Table 1.
C282Y Associations with Outcomes Adjusted for 
Technical Covariates
C282Y homozygote men aged 60–70 years (n = 593/95,137) were 
2.38 times more likely to have sarcopenia (odds ratio [OR] 2.38, 
95% confidence interval [CI] 1.80–3.13, p = 9.7 × 10−10, compared 
to the common “wild-type” genotype; 9.95% vs 4.24% in wild type 
[Table 1, Figure 1]). The association with grip strength (OR 1.69, 
95% CI 1.39–2.05, p = 9.81 × 10−08) was stronger than the asso-
ciation with muscle mass (OR 1.20, 95% CI 1.02–1.41, p = .032). 
C282Y homozygosity was also associated with increased likelihood 
of frailty (OR 2.01, 95% CI 1.45–2.80, p = 3.41 × 10−05; 7.7% vs 
3.6%). Chronic pain experienced for ≥3  months at ≥1 site (hip, 
knee, headache, back, and neck/shoulder pain) was more common in 
homozygous men (OR 1.23, 95% CI 1.05–1.45, p = .01; 47.7% of 
C282Y homozygous men vs 42.0% in wild type) including hip (OR 
1.51, 95% CI 1.19–1.92, p = .0008), back (OR 1.31, 95% CI 1.08–
1.60, p = .0072), neck/shoulder pain (OR 1.32, 95% CI 1.08–1.62, 
p = .0079), and diagnosis of polymyalgia rheumatica (OR 3.36, 95% 
CI 1.37–8.21, p =  .01) (see Figure 1, Table 1, and Supplementary 
Table 2).
C282Y homozygote women (n = 719/105,838) were not signifi-
cantly more likely to have sarcopenia or frailty overall across the 
60–70 age range. C282Y homozygote women aged 60–64  years 
(n  =  407/60,954) did not have excess frailty, but an association 
was present in C282Y homozygote women aged 65–70  years 
(n = 312/44,884), possibly due to longer exposure to iron overload 
postmenopause (OR 1.73, 95% CI 1.05–2.84, p = .032). Associations 
were also present for exhaustion (OR 1.51, 95% CI 1.08–2.11, 
p =  .016) and unintentional weight loss (OR 1.41, 95% CI 1.05–
1.88, p = .021). Similar to the men, C282Y homozygote women aged 
65–70 years were also more likely to have pain at the hips (OR 1.38, 
95% CI 1.03–1.85, p = .033), back (OR 1.39, 95% CI 1.07–1.80, 
p = 0.0121), and in contrast to the men, knee pain (OR 1.46, 95% CI 
1.13–1.87, p = .004) (see Figure 1, Supplementary Table 3)
Sensitivity Analyses
We repeated analyses for the four main outcomes including an inter-
action term between C282Y genotype and daily alcohol intake. The 
only outcome in men or women in which alcohol intake signifi-
cantly interacted with C282Y homozygosity status was sarcopenia 
in 65–70-year-old women (int-p = .035), with a stronger association 
observed in daily drinkers. Analyses including an interaction term 
for current smoking status showed no significant interactions.
In additional sensitivity analyses, we excluded one of each pair of 
genetically related participants (to the third-degree or closer, 32,736 
of 200,975 excluded, 16.3%), to remove familial effects which can 
inflate genetic associations. In men aged 60–70  years, all C282Y 
Table 1. Description of the Sample of 60–70 Year Old UK Biobank Participants by C282Y Genotype and Sex
Men
60–70 y Old
Women
60–70 y Old
Number of C282Y copies -/- C282Y/- C282Y/C282Y -/- C282Y/- C282Y/C282Y
N (%) 80,945 (85.08) 13,599 (14.29) 593 (0.62) 90,214 (85.24) 14,905 (14.08) 719 (0.68)
Age, mean (SD) 64.24 (2.86) 64.19 (2.85) 64.19 (2.84) 64.04 (2.84) 64.02 (2.86) 64.26 (2.82)
Prevalent Hereditary hemochromatosis  
diagnosis, n (%)
35 (0.04) 31 (0.23) 81 (13.66) 5 (0.01) 7 (0.05) 34 (4.73)
Chronic pain, n (%)
 Chronic pain in ≥1 sites 33,987 (41.99) 5,819 (42.79) 283 (47.72) 4,1745 (46.27) 6,960 (46.70) 339 (47.15)
 Hip pain 3 mo 7,068 (8.76) 1,267 (9.35) 77 (13.03) 10,939 (12.18) 1,853 (12.49) 105(14.71)
 Knee pain 3 mo 15,305 (18.97) 2,606 (19.25) 125 (21.22) 17,115 (19.06) 2,931 (19.77) 154 (21.51)
 Back pain 3 mo 13,842 (17.16) 2,385 (17.61) 127 (21.53) 16,805 (18.72) 2,795 (18.86) 150 (21.01)
 Neck/shoulder pain 3 mo 12,067 (14.96) 2,028 (14.98) 114 (19.32) 15,589 (17.37) 2,659 (17.93) 115 (16.13)
 Headache 3 mo 3,589 (4.45) 557 (4.11) 31 (5.25) 7,174 (8.00) 1,162 (7.85) 52 (7.29)
Prevalent Polymyalgia rheumatica, n (%) 204 (0.25) 48 (0.35) 5 (0.84) 520 (0.58) 92 (0.62) 1 (0.14)
Frailty, n (%)
 Frailty (3+ of 5 Fried criteria) 2,572 (3.62) 431 (3.61) 39 (7.65) 2,773 (3.66) 469 (3.75) 28 (4.84)
 Weight loss 11,050 (14.02) 1,914 (14.47) 91 (15.72) 13,226 (15.05) 2,159 (14.87) 125 (17.96)
 Exhaustion 6,455 (8.32) 1,085 (8.31) 68 (11.93) 8,629 (10.06) 1,365 (9.65) 76 (11.38)
 Low grip strength 11,972 (15.00) 2,016 (15.04) 139 (23.68) 12,047 (13.53) 1,990 (13.53) 107 (15.07)
 Slow walking speed 8,114 (10.21) 1,370 (10.28) 78 (13.33) 8,493 (9.58) 1,459 (9.96) 70 (9.94)
 Low physical activity 14,673 (19.81) 2,379 (19.09) 108 (20.26) 16,298 (20.40) 2,779 (21.05) 129 (20.84)
Sarcopenia, n (%) 3,341 (4.24) 621 (4.69) 57 (9.95) 11,158 (12.65) 1,893 (13.00) 105 (15.00)
 Low muscle mass, n (%) 34,629 (43.82) 6,008 (45.28) 279 (48.61) 46,125 (52.11) 7,754 (53.02) 381 (54.12)
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homozygous status associations remained, with the exception of 
sarcopenia muscle mass definition (OR 1.14, 95% CI 0.95–1.36, 
p = .17), although point estimates were similar (full sample OR 1.20, 
95% CI 1.02–1.41, p  =  .032). A nominally significant association 
with slow walking speed became statistically significant (p = .05). In 
women aged 65–70 years, associations with exhaustion, Fried frailty, 
chronic knee, and back pain remained (p < .05), but the associations 
with unintentional weight loss and chronic hip pain became nonsig-
nificant (p > .05) (Supplementary Table 4)
We tested whether the associations between C282Y and frailty 
or chronic pain were robust to excluding 193 participants (0.1% of 
200,975) with a diagnosis of hemochromatosis (either self-reported or 
from the hospital admission data at baseline); in men aged 60–70 years, 
associations with neck/shoulder and hip pain became nonsignificant; 
and in women aged 65–70 years, associations with chronic hip pain 
became nonsignificant (p > .05, see Supplementary Table 5).
We also carried out additional sensitivity analysis exclud-
ing participants with missing data for one or more outcomes 
(n = 31,898/200,975). Results were largely unchanged but in men 
aged 60–70  years, a nominally significant association with slow 
walking speed became significant (p = .04) but the association with 
back pain became nonsignificant. In women aged 65–70 years, asso-
ciations with unintentional weight loss and chronic hip pain became 
nonsignificant (p > .05, see Supplementary Table 6).
Discussion
Iron is a key contributor for accelerated oxidative damage in aging 
(28), yet little was known of the effects of the hemochromatosis HFE 
C282Y mutation in older people. In the large UK Biobank volunteer 
cohort, we found that both male and female older C282Y homozy-
gotes were significantly more likely to have sarcopenia, frailty, and 
chronic pain, compared to the wild-type (common) variant. They 
were also more likely to be diagnosed with polymyalgia rheumatica, 
although numbers of cases were small. Associations with C282Y 
were more pronounced in men than women, a pattern typical of 
HH and often attributed to the “natural therapeutic” effect of 
repeated blood loss with menstruation in premenopausal women 
(6). However, in the (virtually all postmenopausal) 65–70-year-
old women, we observed similar associations to men, with C282Y 
homozygosity associated with frailty, exhaustion, and hip pain. In 
addition, women experienced more unintentional weight loss.
Figure 1. Frailty, sarcopenia, and chronic pain associations with C282Y homozygosity. Forest plot showing odds ratios by health measures comparing C282Y 
homozygous subjects to those with the common genotype, by sex and age group. Logistic regression models adjusted for age and technical covariates. C282Y 
homozygote men aged 60–70 years (n = 593/95,137); aged 60–64 years (n = 315/51,331); and aged 65–70 years (n = 278/43,806). C282Y homozygote women aged 
60–70 years (n = 719/105,838); aged 60–64 years (n = 407/60,954); and aged 65–70 years (n = 312/44,884). Polymyalgia rheumatica is not in the figure because 
there were too few observations for the subgroup analyses (see Supplementary Tables 1 and 2).
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We used the Fried Frailty definition, which was derived on a 
population of noninstitutionalized ≥65-year olds (21) with an esti-
mated 6.9% meeting criteria: this prevalence is somewhat higher 
than the 4.0% frailty prevalence in the studied UK Biobank com-
munity volunteer sample aged 60–70  years at baseline. We used 
a modified version of the Fried frailty phenotype of which four 
of the five variables were self-reported; so, there is a small risk of 
misclassification from reporting bias. However, one study assess-
ing self-reported Fried frailty compared to the measured pheno-
type actually found it was more discriminatory and predictive of 
adverse outcomes (29). As far as we are aware, there are no previ-
ous studies of sarcopenia or frailty in C282Y homozygotes. Joint 
pain in HH is typically initially reported in hand joints (proximal 
interphalangeal and metacarpophalangeal joints) (30), while some 
studies mention foot and hip joint pain (13). Unfortunately, no 
data were available on hand pain in UK Biobank. To the best of our 
knowledge, the association reported here with back pain is novel. 
The previous literature on HH generally suggests that large joint 
symptoms are possible but not characteristic of HH, but it is clear 
from our results that large joint pain is more common in older 
C282Y homozygotes.
Possible mechanisms for the associations between C282Y 
homozygosity and excess sarcopenia, frailty, and chronic pain is the 
deposition of excess iron in widespread parenchymal tissue leading 
to the production of toxic free radicals with resulting oxidative dam-
age (6,11). Iron has also been linked to the inflammatory response 
and to mitochondrial dysfunction (15). However, further work is 
needed to explore specific mechanistic pathways.
This is the largest study to date with HFE genotyping in an 
older sample. The UK Biobank participants were volunteers, 
and the sample was enriched for lower behavioral risks and bet-
ter health status at baseline (18). However, the prevalence of the 
C282Y variant is similar to previous reports for groups of British 
and Irish ancestry (2). We have no data on timing of hemochro-
matosis diagnosis (ie, whether the first diagnosis was from tracing 
of family members, mild symptoms or after established morbid-
ity, etc.) or receipt of treatment. Data are also not available on 
iron, ferritin, or transferrin measures. Future work is needed to 
address the longer term outcomes, especially in women as time 
from menopause and iron deposition increases. As many people 
with C282Y-associated HH are currently not diagnosed or diag-
nosed only after pathology is well established and treatment is 
likely to be less effective, new clinical approaches are needed to 
achieve early ascertainment. It is interesting to note that models 
suggest that targeted population screening for the HFE C282Y 
homozygous status would be cost effective (31), even before our 
new findings reported substantial later life sarcopenia, frailty, and 
chronic pain.
Conclusion
HFE C282Y homozygosity is associated with substantial excess 
sarcopenia, frailty, and chronic pain at older ages. A higher index 
of clinical suspicion may be needed in considering this causation in 
older European descent patients presenting with joint pain, sarcope-
nia, and frailty. Given the availability of often simple, inexpensive, 
and benign prevention and treatment, HH is a strong candidate for 
precision medicine approaches to prevent and manage sarcopenia, 
frailty, and pain in later life.
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